Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

Venmax Drugs & Pharmaceuticals Q4 FY26 Results: Net Profit ₹0.1 Cr, Down 87.5% YoY

Venmax Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹3.9 Cr (+1200.0% YoY) and net profit of ₹0.1 Cr (-87.5% YoY) for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations3.91.60.3
Other income0.10.11.0
Total income4.01.61.4
Profit before exceptional items & tax0.10.00.8
Profit before tax0.10.00.8
Net profit0.10.00.8
Operating margin2.5%0.0%57.1%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Net profit, year on year-87.50%
Revenue, year on year+1200.00%
Source

BSE results filing, NSE: VENMAX. Figures extracted from the filing.

Read the filing ↗

Venmax Drugs & Pharmaceuticals Ltd: key numbers

Share price
₹15.01
Market cap
₹13.18 Cr
Revenue (annual)
₹8.02 Cr
Net profit (annual)
₹0.25 Cr
P/E (TTM)
47.0×Sector 50.4×
Promoter holding
10.46%-3.34% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Venmax Drugs & Pharmaceuticals Ltd

All →
13:43 IST BSE
Annual General Meeting

Venmax Drugs & Pharmaceuticals Annual General Meeting

Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.

22:13 IST BSE
Acquisition

Venmax Drugs & Pharmaceuticals Acquisition

Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.

14:13 IST BSE
Acquisition

Venmax Drugs & Pharmaceuticals Acquisition

NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.